Educational & Guideline Reference Notice: Unranked FDA-label and national guideline option categories and recruiting clinical trials for discussion with a licensed oncologist. Protocol drug dosing and autonomous treatment prescriptions are excluded.
Non-Small Cell Lung Cancer (NSCLC) — 46 Curated Clinical Trials
| NCT Identifier | Title & Sponsor | Phase / Status |
|---|---|---|
| NCT03175224 | APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | PHASE2 RECRUITING |
| NCT03191149 | Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | PHASE2 RECRUITING |
| NCT03851445 | Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | PHASE2/PHASE3 RECRUITING |
| NCT04410796 | Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | PHASE2 RECRUITING |
| NCT04486833 | Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib | PHASE1/PHASE2 RECRUITING |
| NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | PHASE2/PHASE3 RECRUITING |
| NCT05099172 | First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epidermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor Receptor 2 (HER2) | PHASE1/PHASE2 RECRUITING |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | PHASE1/PHASE2 RECRUITING |
| NCT05150691 | A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | PHASE1/PHASE2 RECRUITING |
| NCT05456256 | A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | PHASE2 RECRUITING |
| NCT05785741 | A Study of DB-1310 in Advanced/Metastatic Solid Tumors | PHASE1/PHASE2 RECRUITING |
| NCT05920356 | A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202) | PHASE3 RECRUITING |
| NCT06010329 | A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC | PHASE2 RECRUITING |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | PHASE1/PHASE2 RECRUITING |
| NCT06090266 | A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents | PHASE1/PHASE2 RECRUITING |
| NCT06116682 | Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial) | PHASE2 RECRUITING |
| NCT06350097 | Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | PHASE3 RECRUITING |
| NCT06449313 | Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features | PHASE2 RECRUITING |
| NCT06495125 | Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer | PHASE2 RECRUITING |
| NCT06582771 | A Study of Sotorasib in People With Non-Small Cell Lung Cancer | PHASE2 RECRUITING |
| NCT06618287 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | PHASE1/PHASE2 RECRUITING |
| NCT06667076 | A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | PHASE2 RECRUITING |
| NCT06706076 | A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations | PHASE1/PHASE2 RECRUITING |
| NCT06745908 | Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy | PHASE3 RECRUITING |
| NCT06750185 | Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors | PHASE1/PHASE2 RECRUITING |
| NCT06772623 | Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | PHASE1/PHASE2 RECRUITING |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors | PHASE1/PHASE2 RECRUITING |
| NCT06890598 | Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | PHASE3 RECRUITING |
| NCT06899126 | Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer | PHASE3 RECRUITING |
| NCT07020221 | A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | PHASE1/PHASE2 RECRUITING |
| NCT07037758 | A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | PHASE1 RECRUITING |
| NCT07100080 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Amivantamab for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | PHASE2/PHASE3 RECRUITING |
| NCT07148128 | Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours. | PHASE1/PHASE2 RECRUITING |
| NCT07154290 | A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) | PHASE2 RECRUITING |
| NCT07154706 | Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV) | PHASE3 RECRUITING |
| NCT07190248 | A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | PHASE3 RECRUITING |
| NCT07252739 | KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) | PHASE2 RECRUITING |
| NCT07287995 | A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors | PHASE1/PHASE2 RECRUITING |
| NCT07393555 | Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial) | PHASE2 RECRUITING |
| NCT07405190 | Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC | PHASE2 RECRUITING |
| NCT07439094 | A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer | PHASE1/PHASE2 RECRUITING |
| NCT07535437 | A Study of Ivonescimab in Combination With Dato-DXd or Osimertinib in People With Non-Small Cell Lung Cancer | PHASE1/PHASE2 RECRUITING |
| NCT07538804 | A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer | PHASE1/PHASE2 RECRUITING |
| NCT07586202 | A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC | PHASE2 RECRUITING |
| NCT07777822 | Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mutated NSCLC | PHASE3 RECRUITING |
| NCT07874490 | Osimertinib and Cyclosporine A to Enhance Antitumor Efficacy in NSCLC | PHASE2 RECRUITING |